



**PB 71 of 2025**

## **National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025**

*National Health Act 1953*

---

I, REBECCA RICHARDSON, as delegate of the Minister for Health and Ageing, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953*.

Dated        26 June 2025

REBECCA RICHARDSON  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division, Health Resourcing Group  
Department of Health, Disability and Ageing

---

# Contents

1 Name.....	3
2 Commencement.....	3
3 Repeal.....	3
4 Authority.....	3
5 Definitions.....	3
<b>Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day .....</b>	<b>4</b>
6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1 .....	4
7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items .....	4
8 Reduction Day .....	4
<b>Part 2 – Brands of pharmaceutical items with a weighted average disclosed price .....</b>	<b>4</b>
9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2 .....	4
<b>Schedule 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day</b>	
<b>Schedule 2 – Brands of pharmaceutical items with a weighted average disclosed price and no reduction day</b>	

## 1 Name

- (1) This instrument is the *National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025*.
- (2) This instrument may also be cited as PB 71 of 2025.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is registered.	

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Repeal

The *National Health (Weighted average disclosed price – April 2025 reduction day) Determination 2024 (PB 146 of 2024)* is repealed.

## 4 Authority

This instrument is made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953*.

## 5 Definitions

Note: A number of expressions used in this instrument are defined in section 99ADB of the Act, including the following:

- (a) adjusted approved ex-manufacturer price;
- (b) data collection period
- (c) unadjusted price reduction;
- (d) weighted average disclosed price.

In this instrument:

**Act** means the *National Health Act 1953*.

## **Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day**

### **6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1**

(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 is the amount specified in column 3 of that table item.

(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 31 March 2025.

Note: Paragraph 99ADH(1)(a) of the Act applies if, under section 99ADB, the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand.

### **7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items**

The adjusted approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of the table to Schedule 1 is the amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 6 of this instrument.

Note: Subsection 99ADB(7) of the Act provides that a determination made under subsection 99ADB(4) in relation to a brand of pharmaceutical item may include the adjusted approved ex-manufacturer price of the brand of pharmaceutical item.

### **8 Reduction Day**

For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 has a reduction day of 1 October 2025.

## **Part 2 – Brands of pharmaceutical items with a weighted average disclosed price**

### **9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2**

(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 2 is the amount specified in column 3 of that table item.

(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 31 March 2025.

Note: This instrument does not determine a reduction day for paragraph 99ADH(1)(aa) of the Act for a brand.